Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipepidine - Taisho Pharmaceutical

Drug Profile

Tipepidine - Taisho Pharmaceutical

Alternative Names: Tipepidine hibenzate; TS 141

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Taisho Pharmaceutical
  • Class Behavioural disorder therapies; Piperidines; Small molecules
  • Mechanism of Action Inwardly rectifying potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 30 Oct 2019 Discontinued - Phase-II for Attention-deficit hyperactivity disorder (In adolescents, In children) in Japan (PO)
  • 01 Oct 2019 TS 141 is still in phase II trials for Attention-deficit hyperactivity disorder in Japan (Taisho Pharmaceuticals website, September 2019)
  • 15 Feb 2018 Taisho Pharmaceutical completes a phase II trial in Attention-deficit hyperactivity disorder (In children, In adolescents) in Japan (PO), before February 2018 (JapicCTI-163244)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top